171 related articles for article (PubMed ID: 34353749)
1. Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.
Farris JC; Hughes RT; Steber CR; Craven TE; Frizzell BA
Brachytherapy; 2021; 20(6):1107-1113. PubMed ID: 34353749
[TBL] [Abstract][Full Text] [Related]
2. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
[TBL] [Abstract][Full Text] [Related]
3. Urinary symptom flare following I-125 prostate brachytherapy.
Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
[TBL] [Abstract][Full Text] [Related]
4. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.
Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Hasegawa M; Fujii T; Konishi N; Fujimoto K
BMC Urol; 2017 Aug; 17(1):62. PubMed ID: 28806948
[TBL] [Abstract][Full Text] [Related]
5. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
[TBL] [Abstract][Full Text] [Related]
6. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
[TBL] [Abstract][Full Text] [Related]
7. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
[TBL] [Abstract][Full Text] [Related]
8. Associations of Clinical and Dosimetric Parameters with Urinary Toxicities after Prostate Brachytherapy: A Long-Term Single-Institution Experience.
Ito M; Makita C; Mori T; Takano H; Kumano T; Matsuo M; Iinuma K; Kawase M; Nakane K; Nakano M; Koie T
Curr Oncol; 2023 Jun; 30(6):5680-5689. PubMed ID: 37366909
[TBL] [Abstract][Full Text] [Related]
9. Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer.
Murakami N; Itami J; Okuma K; Marino H; Nakagawa K; Ban T; Nakazato M; Kanai K; Naoi K; Fuse M
Strahlenther Onkol; 2008 Oct; 184(10):515-9. PubMed ID: 19016040
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation.
Crook J; McLean M; Catton C; Yeung I; Tsihlias J; Pintilie M
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):453-60. PubMed ID: 11872292
[TBL] [Abstract][Full Text] [Related]
11. Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost.
Ben Aicha I; Hathout L; Carignan D; Després P; Lavallée MC; Aubin S; Beaulieu L; Lacroix F; Foster W; Martin AG; Vigneault E
Brachytherapy; 2020; 19(5):584-588. PubMed ID: 32928485
[TBL] [Abstract][Full Text] [Related]
12. Comparison of patient-reported acute urinary and sexual toxicity scores in a 6- versus 2-fraction course of high-dose-rate prostate brachytherapy monotherapy.
Ragab O; Banerjee R; Park SJ; Patel S; Zhang M; Wang J; Velez M; Demanes DJ; Kamrava M
J Med Imaging Radiat Oncol; 2018 Feb; 62(1):109-115. PubMed ID: 28856847
[TBL] [Abstract][Full Text] [Related]
13. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.
Thomas C; Keyes M; Liu M; Moravan V
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
15. Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy.
Ferro A; Bae HJ; Yenokyan G; Le Y; McNutt T; Mian O; Gergis C; Haviland C; DeWeese TL; Song DY
Brachytherapy; 2018; 17(2):313-318. PubMed ID: 29174937
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study.
Henderson A; Ismail AK; Cunningham M; Aldridge S; Loverock L; Langley SE; Laing RW
Clin Oncol (R Coll Radiol); 2004 Apr; 16(2):95-104. PubMed ID: 15074730
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Long-term Changes in Lower Urinary Tract Symptoms in Patients With Prostate Cancer Who Underwent Low-dose-rate Prostate Brachytherapy.
Iinuma K; Nakano M; Kato T; Kato D; Takai M; Maekawa YM; Nakane K; Mizutani K; Tsuchiya T; Ishihara T; Ito M; Matsuo M; Koie T
Urology; 2020 Aug; 142():213-220. PubMed ID: 32416115
[TBL] [Abstract][Full Text] [Related]
18. The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL.
Dallas NL; Malone PR; Jones A; Doggart AJ; McConway KJ; Rogers PB
BJU Int; 2012 Aug; 110(3):383-90. PubMed ID: 22332791
[TBL] [Abstract][Full Text] [Related]
19. The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Allen ZA; Lief JH; Hinerman-Mulroy A; Galbreath RW
Cancer J; 2004; 10(3):181-9. PubMed ID: 15285928
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
